Intimation of the Unaudited Financial Results along with the Limited Review Report for the Quarter and half year ended September 30, 2026

Evonile Pharma Limited (formerly known as Novartis India Limited) November 03, 2026 The Secretary, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001. Scrip Code: 500672 Sub: Outcome of the Meeting of the Board of Directors of Evonile Pharma Limited (formerly known as Novartis India Limited) (“the Company”) held on Tuesday, November 03, 2026 Dear Sir/ Madam, In continuation to our intimation dated Wednesday, September 30, 2026, and pursuant to Regulations 30 (read with Part A, Para A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’) read with the relevant circulars issued by SEBI (‘SEBI Circular’), we hereby inform that the Board of Directors (‘Board’) of the Company at its Meeting held today i.e. Tuesday, November 03, 2026, inter-alia have considered and approved the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026 and the Limited Review Report dated Tuesday, November 03, 2026, as recommended by the Audit Committee, issued by the Statutory Auditors of the Company and the same is taken on record by the Board of the Company. The said Meeting commenced at 06:06 P.M. (IST) and concluded at 06:26 P.M. (IST). In terms of Regulation 33 of SEBI Listing Regulations, please find enclosed herewith: a) The Unaudited Financial Results for the quarter and half year ended September 30, 2026; (Annexure- b) Limited Review Report dated Tuesday, November 03, 2026, issued by the Statutory Auditors of the Company with respect to the Unaudited Financial Results and the same as taken on record by the Board of the Company (Annexure-II) The above is for your information and the same is also available on the website of the Company i.e. https://evonilepharma.com/quarterly-reports/ Kindly take the above on record. For Evonile Pharma Limited (Formerly known as Novartis India Limited) Chandni Maru Company Secretary & Compliance Officer A60291 Encl: as above Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@evonilepharma.com | Website: www.evonilepharma.com